CASI Pharmaceuticals Inc (CASI) Given “Buy” Rating at Maxim Group
CASI Pharmaceuticals Inc (NASDAQ:CASI)‘s stock had its “buy” rating reissued by analysts at Maxim Group in a research note issued on Wednesday. They presently have a $4.00 price objective on the stock. Maxim Group’s price target would indicate a potential upside of 280.95% from the stock’s previous close.
CASI Pharmaceuticals (NASDAQ:CASI) traded down 1.87% during mid-day trading on Wednesday, reaching $1.05. The company had a trading volume of 2,168 shares. The firm has a 50-day moving average of $1.11 and a 200 day moving average of $1.18. The company’s market capitalization is $51.93 million. CASI Pharmaceuticals has a 1-year low of $0.58 and a 1-year high of $1.82.
CASI Pharmaceuticals (NASDAQ:CASI) last posted its earnings results on Monday, August 15th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.04. On average, analysts predict that CASI Pharmaceuticals will post ($0.16) earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/casi-pharmaceuticals-inc-casi-given-buy-rating-at-maxim-group.html
In other news, major shareholder Byte Ltd Sparkle bought 3,753,855 shares of the stock in a transaction on Friday, June 24th. The shares were bought at an average price of $1.19 per share, with a total value of $4,467,087.45. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.